We compared the effects of a nitrogen-containing bisphosphonate (N-BP), zoledronic acid (ZA), and an anti-mouse RANKL antibody (anti-mRANKL Ab) on the bone tissue pathology of a transgenic mouse model of human fibrous dysplasia (FD). For comparison, we also reviewed the histological samples of a child with McCune–Albright syndrome (MAS) treated with Pamidronate for 3 years. EF1α-GsαR201C mice with FD-like lesions in the tail vertebrae were treated with either 0.2 mg/kg of ZA at day 0, 7, and 14 or with 300 μg/mouse of anti-mRANKL Ab at day 0 and 21. All mice were monitored by Faxitron and histological analysis was performed at day 42. ZA did not affect the progression of the radiographic phenotype in EF1α-GsαR201C mice. FD-like lesions in the ZA group showed the persistence of osteoclasts, easily detectable osteoclast apoptotic activity and numerous “giant osteoclasts”. In contrast, in the anti-mRANKL Ab-treated mice, osteoclasts were markedly reduced/absent, the radiographic phenotype reverted and the FD-like lesions were extensively replaced by newly formed bone. Numerous “giant osteoclasts” were also detected in the samples of the child with MAS. This study supports the hypothesis that osteoclasts per se, independently of their resorptive activity, are essential for development and expansion of FD lesions.

Zoledronic acid in a mouse model of human fibrous dysplasia: ineffectiveness on tissue pathology, formation of “giant osteoclasts” and pathogenetic implications / Corsi, A.; Palmisano, B.; Spica, E.; Di Filippo, A.; Coletta, I.; Dello Spedale Venti, M.; Labella, R.; Fabretti, F.; Donsante, S.; Remoli, C.; Serafini, M.; Riminucci, M.. - In: CALCIFIED TISSUE INTERNATIONAL. - ISSN 0171-967X. - 107:6(2020), pp. 603-610. [10.1007/s00223-020-00752-w]

Zoledronic acid in a mouse model of human fibrous dysplasia: ineffectiveness on tissue pathology, formation of “giant osteoclasts” and pathogenetic implications

Corsi A.
Primo
;
Palmisano B.
Secondo
;
Spica E.;Coletta I.;Dello Spedale Venti M.;Labella R.;Fabretti F.;Donsante S.;Remoli C.;Riminucci M.
Ultimo
2020

Abstract

We compared the effects of a nitrogen-containing bisphosphonate (N-BP), zoledronic acid (ZA), and an anti-mouse RANKL antibody (anti-mRANKL Ab) on the bone tissue pathology of a transgenic mouse model of human fibrous dysplasia (FD). For comparison, we also reviewed the histological samples of a child with McCune–Albright syndrome (MAS) treated with Pamidronate for 3 years. EF1α-GsαR201C mice with FD-like lesions in the tail vertebrae were treated with either 0.2 mg/kg of ZA at day 0, 7, and 14 or with 300 μg/mouse of anti-mRANKL Ab at day 0 and 21. All mice were monitored by Faxitron and histological analysis was performed at day 42. ZA did not affect the progression of the radiographic phenotype in EF1α-GsαR201C mice. FD-like lesions in the ZA group showed the persistence of osteoclasts, easily detectable osteoclast apoptotic activity and numerous “giant osteoclasts”. In contrast, in the anti-mRANKL Ab-treated mice, osteoclasts were markedly reduced/absent, the radiographic phenotype reverted and the FD-like lesions were extensively replaced by newly formed bone. Numerous “giant osteoclasts” were also detected in the samples of the child with MAS. This study supports the hypothesis that osteoclasts per se, independently of their resorptive activity, are essential for development and expansion of FD lesions.
2020
denosumab; fibrous dysplasia; giant osteoclasts; nitrogen-containing bisphosphonates; zoledronic acid
01 Pubblicazione su rivista::01a Articolo in rivista
Zoledronic acid in a mouse model of human fibrous dysplasia: ineffectiveness on tissue pathology, formation of “giant osteoclasts” and pathogenetic implications / Corsi, A.; Palmisano, B.; Spica, E.; Di Filippo, A.; Coletta, I.; Dello Spedale Venti, M.; Labella, R.; Fabretti, F.; Donsante, S.; Remoli, C.; Serafini, M.; Riminucci, M.. - In: CALCIFIED TISSUE INTERNATIONAL. - ISSN 0171-967X. - 107:6(2020), pp. 603-610. [10.1007/s00223-020-00752-w]
File allegati a questo prodotto
File Dimensione Formato  
Corsi_Zoledronic_2020.pdf

accesso aperto

Note: https://link.springer.com/article/10.1007/s00223-020-00752-w
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.46 MB
Formato Adobe PDF
1.46 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1444603
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact